[1] TSAI C H,HILL M,ASA S L,et al.Intestinal growth-promoting properties of glucagon-like peptide-2 in mice[J].American Journal of Physiology-Endocrinology and Metabolism,1997,273(1):E77-E84.
[2] GUAN X F,STOLL B,LU X F,et al.GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets[J].Gastroenterology,2003,125(1):136-147.
[3] BENJAMIN M A,MCKAY D M,YANG P C,et al.Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse[J].Gut,2000,47(1):112-119.
[4] WØJDEMANN M,WETTERGREN A,HARTMANN B,et al.Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2[J].The Journal of Clinical Endocrinology & Metabolism,1999,84(7):2513-2517.
[5] PEDERSEN N B,HJOLLUND K R,JOHNSEN A H,et al.Porcine glucagon-like peptide-2:structure,signaling,metabolism and effects[J].Regulatory Peptides,2008,146(1/2/3):310-320.
[6] JEPPESEN P B,PERTKIEWICZ M,MESSING B,et al.Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure[J].Gastroenterology,2012,143(6):1473-1481.
[7] ALTERS S E,MCLAUGHLIN B,SPINK B,et al.GLP2-2G-XTEN:a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model[J].PLoS One,2012,7(11):50630.
[8] QI K K,WU J,DENG B,et al.PEGylated porcine glucagon-like peptide-2 improved the intestinal digestive function and prevented inflammation of weaning piglets challenged with LPS[J].Animal,2015,9(9):1481-1489.
[9] QI K K,WU J,WAN J,et al.Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis[J].Peptide,2014,52:11-18.
[10] WU J,QI K K,XU Z W,et al.Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model[J].Journal of Microencapsulation,2015,32(6):598-607.
[11] DRUCKER D J,ERILICH P,ASA S L,et al.Induction of intestinal epithelial proliferation by glucagon-like peptide 2[J].Proceedings of the National Academy of Sciences of the United States of America,1996,93(15):7911-7916.
[12] BOUSHEY R P,YUSTA B,DRUCKER D J.Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis[J].American Journal of Physiology:Endocrinology and Metabolism,1999,277(5):E937-E947.
[13] DRUCKER D J,YUSTA B,BOUSHEY R P,et al.Human[Gly
2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis[J].American Journal of Physiology:Gastrointestinal and Live Physiology,1999,276(1):G79-G91.
[14] ALAVI K,SCHWARTZ M Z,PALAZZO J P,et al.Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2[J].Journal of Pediatric Surgery,2000,35(6):847-851.
[15] BAILON P,WON C Y.PEG-modified biopharmaceuticals[J].Expert Opinion on Drug Delivery,2009,6(1):1-16.
[16] HARRIS J M,CHESS R B.Effect of pegylation on pharmaceuticals[J].Nature Reviews Drug Discovery,2003,2(3):214-221.
[17] VERONESE F M,PASUT G.PEGylation,successful approach to drug delivery[J].Drug Discovery Today,2005,10(21):1451-1458.
[18] FEE C J,ALSTINE J M V.PEG-proteins:reaction engineering and separation issues[J].Chemical Engineering Science,2006,61(3):924-939.
[19] LEE S H,LEE S,YOUN Y S,et al.Synthesis,characterization and pharmacokinetic studies of PEGylated glucagon-like peptide-1[J].Bioconjugate Chemistry,2005,16(2):377-382.
[20] CHOI S,BAUDYS M,KIM S W.Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats[J].Pharmaceutical Research,2004,21(5):827-831.
[21] 刘琳娜,李欣,张琰等.胰高血糖素样肽-2/聚乳酸-羟基乙酸微球的制备及其体外释药性质研究[J].中国药房,2010(29):2755-2757.
[22] 张海松,刘卫红,张基展,等.口服胸腺肽微球在大鼠体内的药代动力学和生物利用度[J].中国生化药物杂志,2000,21(1):15-17.
[23] 陆蕾.干扰素α-2b PLGA缓释微球药代动力学及药效学研究[D].硕士学位论文.上海:第二军医大学,2006:18-29.
[24] 肖田安,怀彬彬,李帅鹏,等.伊维菌素PLA及PLGA微球混悬液在犬体内的药代动力学研究[J].华南农业大学学报,2014,35(3):8-12.
京公网安备 11010802041926号